Universal Biosensors (ASX: UBI) – electrochemical cell technology
COMPANY SCOREBOARD
| Pro Plus | Pro | Con Plus | Con |
|
|
ABOUT COMPANY
Universal Biosensors (UBI) (https://www.universalbiosensors.com/) develops biosensor and electrochemical cell technology. The company currently commercilises two main products: Sentia for the wine industry and Xprecia Prime for the healthcare sector. Sentia detects the presence of fructose and glucose, titratable acidity, and acetic acid in wine.
CAPITAL STRUCTURE
| ASX Code | Share Price | Shares | Option (In) | Market Cap | Cash/Asset ($m) |
| UBI | 0.2 | 212369435 | 2364666 | 42946820.2 | 9.3/0 |
| Holders No | Top 20 (Cur) | Top 20 (Pre) | Director Hold | Performance Right | Note |
| 4.91% | 9425000 | last raise $25m@77c |
The company CEO, John Sharman, was the CEO of MVP for ten years. He increased the shareholder value from A$7 million (in 2010) to over A$700m million.
BUSINESS
Below is the company’s five years performance:
| UBI | 2022 | 2021 | 2020 | 2019 | 2018 |
| Operation Revenue (US$) | 4524962 | 5777751 | 3202609 | ||
| Cost of Sale | -2385931 | -3672057 | -2579523 | ||
| Gross Revenue | 2139031 | 2105694 | 623086 | 0 | 0 |
| Gross Margin | 0.4727 | 0.3644 | 0.1946 | 0 | 0 |
| Overheads | -23368252 | -14967027 | -10954329 | ||
| Fixed Overheads | |||||
| Variable Overheads | |||||
| Total Operation Expense | -23368252 | -14967027 | -10954329 | 0 | 0 |
| Operation Profit | -21229221 | -12861333 | -10331243 | 0 | 0 |
| Other Revenue | -6158999 | 4572895 | 4829814 | ||
| Interest Expense | 164076 | -71963 | 139016 | ||
| D&A | -2649671 | -2176751 | -2226940 | ||
| Income Tax | 3050837 | ||||
| Net Profit | -26822978 | -10537152 | -7589353 | 0 | 0 |
| NOTES | $11m impairment |
SUMMARY
The company has a substantial ground to recover when it comes to products sale.